Coxsackievirus A21 Synergizes with Checkpoint Inhibitors [News in Brief]

Treatment with a combination of a proprietary formulation of coxsackievirus and either an anti–CTLA-4 or anti–PD-1 checkpoint inhibitor yielded a higher response rate in phase I testing for melanoma than any of these drugs given on their own. Because the viral therapy adds little toxicity, it might prove an effective part of a dual regimen, according to interim trial data presented at the American Association for Cancer Research Annual Meeting 2017.

http://ift.tt/2qMMkK1